Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01604343 · ClinicalTrials.gov registry record · Phase 3
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,670
- Enrollment target
NCT01604343 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 1,670 participants.
The verdict
NCT01604343, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,670 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) and inhibition of radiographic progression in patients with active RA who are unresponsive to treatment with disease-modifying antirheumatic drugs (DMARD).
Interventions
- DRUG Placebo
- DRUG Sirukumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,670 participants |
| Start Date | 2012-08-15 |
| Est. Completion | 2016-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01604343
The ClinicalTrials.gov registry entry for NCT01604343 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01604343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01604343 about?
NCT01604343 is a clinical study titled "A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)". The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) and inhibition of radiographic progression in patients with active RA who are unresponsive to treatment with disease-modifying antirheumatic drugs (DMA...
What is the current status of trial NCT01604343?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,670 participants. The study started on 2012-08-15. Estimated completion is 2016-12-06.
What interventions are being tested in trial NCT01604343?
The interventions under investigation include: Placebo (DRUG), Sirukumab (DRUG).
Who is sponsoring clinical trial NCT01604343?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.